Phenylpiracetam appears on the World Anti-Doping Agency (WADA) Prohibited List as a stimulant analog. As a close structural derivative, RGPU-95 is expected to fall within the same or an analogous prohibited category. This compound is not approved by any regulatory authority for human use and is supplied exclusively for qualified laboratory research.

• Choline Precursors (Alpha-GPC, Citicoline): Support cholinergic substrate availability; relevant given RGPU-95’s proposed nAChR interactions. Useful in paradigms examining combined glutamatergic-cholinergic modulation.
• Other AMPA PAMs (Aniracetam, Noopept): Potential additive effects at the AMPA receptor. Use dose-response matrices to distinguish additive from supra-additive interactions; risk of over-excitation at high combined concentrations.

• ⚠️ Serotonergic Agents (SSRIs, 5-HTP): Interaction profile unknown; potential for additive effects on affective behavioral measures. Include appropriate washout periods and separate experimental groups.
• ⚠️ Dopaminergic Precursors (L-Tyrosine, L-DOPA): Given RGPU-95’s monoaminergic-adjacent profile, combination with direct dopamine precursors may confound interpretation of behavioral endpoints. Characterize individually first.
• 🚫 GABAergic Agents / Seizure Medications: Functionally oppose the glutamatergic enhancement mechanism; combination may produce paradoxical or difficult-to-interpret results. Do not co-administer without explicit study design justification.
• 🚫 Pro-convulsant Compounds: AMPA PAMs lower the threshold for excitotoxic events at high concentrations. Avoid co-administration with compounds that independently reduce seizure threshold.
• 🚫 NMDA Antagonists (Concurrent): Simultaneous AMPA enhancement and NMDA blockade produces complex, unpredictable plasticity effects. Separate mechanistic studies before designing co-administration paradigms.

• 🚫 Not for use in pregnant or lactating models.
• 🚫 Not for juvenile models without specific developmental neuroscience justification; baseline neuroplasticity is maximal in developing animals and may confound interpretation.
• ⚠️ Caution in seizure-prone models. AMPA positive modulation lowers excitotoxic threshold; use with appropriate seizure monitoring in susceptible strains.
• ⚠️ Caution in anticoagulation studies. Flavonoid-adjacent scaffold may interact with clotting pathway assays; verify in your specific model.

How does RGPU-95 differ structurally and pharmacologically from Phenylpiracetam?

Structurally, RGPU-95 differs by a single modification: a chlorine atom at the para position (C-4′) of the phenyl ring. The pyrrolidone core and acetamide tail of the racetam scaffold are conserved. Pharmacologically, RGPU-95 (as the R-enantiomer) is reported to produce comparable qualitative effects to Phenylpiracetam at approximately 2–5× lower doses in rodent behavioral models.

Why is only the R-enantiomer used? What about the S-isomer?

Consistent with the broader racetam SAR literature, the (R)-enantiomer demonstrates substantially greater binding affinity and behavioral efficacy than the (S)-enantiomer in AMPA receptor assays. The designation “RGPU-95” in published patent literature refers specifically to the (R)-4-(4-chlorophenyl)-2-oxopyrrolidine-1-acetamide.

Can RGPU-95 be combined with other AMPA PAMs in the same experiment?

Co-administration with other AMPA positive allosteric modulators is theoretically additive at the receptor level. In practice, combined AMPA PAM dosing carries an elevated risk of excitotoxic overstimulation at the synapse. Establish dose-response curves individually first and monitor behavioral toxicity markers.

How should tolerance be managed in chronic dosing paradigms?

The parent compound Phenylpiracetam is well-documented to show behavioral tolerance within 2–3 days of continuous daily administration. Recommended protocol: Administer for no longer than 3 consecutive weeks, followed by a minimum 7-day washout.

Why does RGPU-95 cost more per gram than Phenylpiracetam?

The synthesis of RGPU-95 requires an additional halogenation step and enantioselective purification to yield the (R)-isomer at high optical purity. However, since the effective research concentration is 2–5× lower than Phenylpiracetam, the cost-per-effective-dose is often comparable.

RGPU-95’s value lies in precision, not volume. Its enhanced potency at the AMPA receptor, combined with its position as a structurally defined single-enantiomer compound, makes it a high-quality reference tool for research groups investigating glutamatergic modulation of cognition.

This compound is manufactured and supplied exclusively for laboratory research and analytical purposes. RGPU-95 has not been evaluated by the FDA, EMA, or any comparable regulatory authority for safety or efficacy. It is not a dietary supplement, pharmaceutical drug, or food ingredient.

The parent compound, Phenylpiracetam, is prohibited by WADA; this compound is expected to carry an analogous prohibited status in competitive sport contexts. The purchaser assumes full responsibility for compliance with all applicable local, national, and international laws and regulations governing the acquisition, possession, use, and disposal of research chemicals.